Extracorporeal Life Support Use in Cardiac and Circulatory Failure: A Summary of Recently Published S3 Guidelines

Review Article
Issue
2022/06
DOI:
https://doi.org/10.4414/cvm.2022.02234
Cardiovasc Med. 2022;25:w02234

Published on 01.11.2022

Introduction

Extracorporeal life support (ECLS) represents a widely accepted treatment modality for patients with cardiac and/or respiratory failure failing to respond to conventional medical therapy. Through the establishment of a modified cardiopulmonary bypass circuit, ECLS provides a mechanism for temporary cardiac support and gas exchange, allowing patients to recover from existing life-threatening cardiac and/or lung disease. This article summarises the current recommendations for ECLS therapy in adults, which are based on the recently published S3 guidelines entitled “Extracorporeal circulation (ECLS / extracorporeal membrane oxygenation = ECMO), use in cardiac and circulatory failure” (Boeken et al. The Thoracic and Cardiovascular Surgeon. In press).

Guidelines

A great number of guidelines have been issued in recent years by the association of the scientific medical societies (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften, AWMF). Medical societies involved in the publication of the current S3 guideline concerning ECLS use in cardiac and circulatory failure are listed in table 1. The level of evidence and the strength of recommendations of ECLS management presented in the current manuscript is high. Detailed description of all S3 guidelines can be found on the AWMF website (www.awmf.org/leitlinien/detail/ll/011-021.html) and were published recently by Boeken and associates (The Thoracic and Cardiovascular Surgeon, in press).
Table 1:
Medical societies involved in the publication of current S3 guidelines concerning extracorporeal life support (ECLS) use in cardiac and circulatory failure.
Deutsche Gesellschaft für Thorax-, Herz- und Gefäßchirurgie e.V. (DGTHG)
Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin e.V. (DGAI)
Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin (DIVI)
Deutsche Gesellschaft für Kardiologie - Herz- und Kreislaufforschung e.V. (DGK)
Gesellschaft für Neonatologie und pädiatrische Intensivmedizin e.V. (GNPI)
Deutsche Gesellschaft für Pädiatrische Kardiologie e.V. (DGPK)
Deutsche Gesellschaft für Internistische Intensivmedizin und Notfallmedizin (DGIIN)
Deutsche Gesellschaft für Innere Medizin e.V. (DGIM)
Deutsche Gesellschaft für Kinder- und Jugendmedizin e.V. (DGKJ)
Deutsche Gesellschaft für Kinderchirurgie (DGKCH)
Deutsche Gesellschaft für Thoraxchirurgie (DGT)
Deutsche Gesellschaft für Fachkrankenpflege und Funktionsdienste e. V. (DGF)
Schweizerische Gesellschaft für Herz- und thorakale Gefässchirurgie (SGHC)
Österreichische Gesellschaft für Thorax- und Herzchirurgie (ÖGTHC)
Deutsche Herzstiftung e.V.
Deutscher Verband für Physiotherapie (ZVK)
Akademie für Ethik in der Medizin (AEM)
Deutsche Gesellschaft für Kardiotechnik e.V. (DGfK)

Staffing issues

A multidisciplinary ECLS team should initiate the ECLS (indication and implantation) in adult patients. The implantation should ideally be in an ECLS centre with sufficient expertise by an ECLS team with appropriate skills in terms of implantation [1, 2]. According to the current literature no minimum number of implantations per year can be defined in order to achieve sufficient therapeutic success with the ECLS. However an implantation rate of at least 20 ECLS per year should be aimed for [3–5]. For the ECLS implantation, a standardised procedure adapted to local conditions should be available in written form [6]. For the ECLS initiation, a specific minimum of medical equipment and facilities should be provided [2, 7].ECLS therapy is to be performed in a centre with a full range of intensive care treatment options in a stan­dardised, multidisciplinary and multimodal approach under the guidance of a specialist experienced in the field of ECLS with an additional qualification in intensive care medicine [2, 8]. Further medical specialists as listed in table 2 should be involved for the management of potential ECLS complications [2, 8].
Table 2:
Disciplines that should be available for the management of extracorporeal life support (ECLS) therapy.
 ECLS initiationECLS ­continuation
Cardiac surgeryXX
CardiologyXX
AnaesthesiologyXX
Intensive care medicineXX
Neurology X
Neurosurgery X
General surgery X
Vascular surgery X
Angiology X
Radiology X
Haematology X
Gastroenterology X
Nephrology X
Pulmonology X
Ethics committee X

Staff training and continuing education

The processes of initiation, further care, training and employee qualification of the multiprofessional ECLS team should be coordinated by the medical director of the ECLS programme, depending on the institutional structure [2, 7, 8].A multiprofessional team specially trained in the ECLS therapy process should carry out the multimodal therapy in that field in the intensive care unit (ICU) [7]. Continuing education of the multiprofessional team in the ICU should take place regularly according to a defined internal curriculum. The training requirement depends on the centre-specific ECLS volume and the individual experience of the medical stuff [2].

ECLS circuit and cannulation site

Only centrifugal pumps should be used for ECLS. Heparin-coated components should preferably be used. The selection of the arterial cannulation site should be based on the patient’s individual circumstances. In adults, either peripheral (femoral artery) or central (subclavian artery; ascending aorta) cannulation can be performed.

Patient ICU care and monitoring

Depending on the medical and nursing effort, in the multidisciplinary approach the patient to nurse ratio in the ICU should be determined individually from shift to shift. The patient’s individual nursing care in the ICU should be ensured [8]. In addition to medical and nursing treatment, technical checks of the ECLS system should be carried out at least once a day by a perfusionist.
Perfusion, haemodynamics, cardiac unloading, oxygenation, anticoagulation and the functionality of the ECLS system should be continuously monitored in patients on ECLS therapy [6, 9, 10]. (figs 1 and 2). Thus a safety net for early detection of possible complication can be established [11–18].
Figure 1:
Patient-related monitoring parameters during extracorporeal life support (ECLS) therapy.
Figure 2:
Monitoring parameters of the extracorporeal life support (ECLS) system.
Every extracorporeal circulation system requires anticoagulation because of contact activation of blood ­coagulation. Anticoagulation is routinely performed with systemic administration of heparin except in ­cases of heparin-induced thrombocytopenia, where ­alternative agents such as argatroban, bivalirudin and lepirudin should be used. Coagulation can be monitored with the use of parameters such as partial thromboplastin time (PTT), activated clotting time (ACT), factor Xa or even thromboelastography.
In patients cannulated in a femoral axis, adequate oxygenation should be monitored by measuring the peripheral oxygen saturation in the right upper extremity and through blood gas analysis of blood samples from arteries of the right upper extremity.
A basic clinical-neurological examination should be carried out daily and the pupillary reflex should be checked several times a day. Due to the lack of reliable data, no additional apparatus-based method for routine neurological monitoring can be recommended.
In the case of femoral arterial cannulation, a distal ­perfusion line should be placed to avoid distal limb ischaemia. In the case of peripheral ECLS cannulation, the arterial cannula should be preferably placed contralaterally to the venous cannula.

Management of ventricular distension and central hypoxia

In the case of left ventricular distension, the left ventricle should be actively unloaded after conservative measures have been exhausted. Various techniques have been described for left ventricular unloading, including open surgical placement of a left ventricular vent, percutaneous left atrial venting, transseptal drainage, intra-aortic balloon pump (IABP) and microaxial blood pump placement in the left ventricle. Retrospective studies have shown that the additional use of a microaxial blood pump (Impella®) placed in the left ventricle was associated with a lower 30-day and 1-year mortality compared with the use of ECLS alone without an increase in complication rates. Even though the additional use of Impella during ECLS has shown an improvement in outcomes, further prospective studies should be conducted to confirm the results of the previous retrospective studies [19–21].
Central hypoxia (watershed or Harlequin syndrome) under ECLS therapy with femoral arterial cannulation should be treated immediately after the diagnosis has been established. The following measures are suitable:
  • Arterial cannulation of right axillary artery.
  • Insertion of another cannula (e.g., via the right internal jugular vein) and change of circuit configuration to veno-arteriovenous (V-AV)
  • Insertion of another venous drainage cannula and change of the configuration to VV-A
  • Change from peripheral to central cannulation.

ECLS weaning and explantation

According to the current literature, there is no evidence for levosimendan therapy as part of ECLS weaning [22].
The following criteria should be evaluated before ECLS weaning is initiated according to the standardised protocol:
  1. Pulsatile arterial blood pressure and evidence of ­biventricular contractility on echocardiography
  2. Mean arterial blood pressure >60 mm Hg
  3. Mixed venous oxygen saturation (SvO2) ≥65% (central venous oxygen saturation [ScvO2] ≥60%)
  4. Lactate values ≤2 mmol/l or falling
  5. Vasopressor/inotropic dosage low or falling
  6. Sufficient pulmonary oxygenation (Horowitz-index or ratio of arterial oxygen partial pressure (PaO2 in mmHg) to fraction of inspired oxygen (FiO2) >200 mm Hg) / CO2 elimination performance under lung-protective ventilation
  7. Compensated end organ functions, especially liver function
In addition, criteria 1–7 should be met with a low ECLS flow (<2.0 l/min) and with a low gas flow (<2 l/min) before ECLS explantation [23, 24]. Pulsatile blood pressure serves as an indication of presence of biventricular contraction, which can be precisely quantified with the help of echocardiography. Furthermore, several retrospective studies have shown that echocardiographic parameters of left and right ventricular function, specifically left ventricular ejection fraction (LVEF), tricuspid annular plane systolic excursion (TAPSE), mitral lateral annular systolic velocity (s’), right ventricle (RV) s’ and left ventricular outflow tract (LVOT) velocity time integral (VTI) are predictors of successful weaning from ECLS (25–27). Due to the complexity of the clinical conditions underlying vasopressor/inotropic therapy, it is difficult to define a target vasopressor/inotropic dose, as a prerequisite for initiating ECLS weaning. However, some orientating doses could be <0.1–0.2 μg/kg/min noradrenaline, <0.1–0.2 μg/kg/min adrenaline, <6 μg/kg/min dobutamine and <2.0 mg/h milrinone [28]. Even though the above-mentioned criteria for weaning should be evaluated before initiating weaning from ECLS, further decision to proceed with weaning should be based on the individual judgement of the medical team involved in the patient’s treatment and after taking into consideration the patient’s general health condition.
During the ECLS weaning process, arterial and central venous blood gas analysis to monitor oxygenation, CO2 elimination and circulatory function should be performed about 30 minutes after the ECLS blood flow has been reduced [9, 10].
An additional mechanical circulatory support system, such as Impella or IABP, should not be routinely implanted during ongoing ECLS treatment (including weaning) [29–34].
Therapy limitations in ECLS patients should be made as a patient-centered decision with the interprofessional treatment team, taking medical and ethical ­aspects into account. Such a scenario exists when the ­desired therapy goal cannot be achieved or the therapy goal is not desired by the patient.
In intensive care patients in the early phase after explantation of an ECLS system, perfusion, haemodynamics (with invasive arterial blood pressure measurement) and oxygenation should be continuously monitored.
Echocardiography should be performed shortly after the ECLS explantation and daily thereafter (early phase after the explantation).
In the early phase after decannulation of a peripherally implanted ECLS system, the cannulation sites should be examined clinically at least once a day.
An ultrasound examination of the cannulated vessels should also be carried out routinely after decannulation.

Normal ward care

As part of the care of patients after ECLS therapy on the normal ward, attention should be given to cardiac deterioration signs and the consequences of cannulation-related complications (infection, thrombosis or ischaemia).

Rehabilitation and follow-up

After ECLS therapy, patients should be rehabilitated in an inpatient setting. Patients should have regular and long-term cardiological follow-up examinations, and depending on the complexity of the underlying disease, in an interdisciplinary special outpatient department.
No financial support and no other potential conflict of interest relevant to this article was reported.
Omer Dzemali
Heart Centre Triemli
Department of Cardiac Surgery
Birmensdorferstrasse 497
CH-8063 Zürich
omer.dzemali[at]stadtspital.ch
1.  Empfehlungen zur extrakorporalen kardiopulmonalen Reanimation (eCPR). Med Klin Intensivmed Notf Med. 2018;113(6):478–86. http://dx.doi.org/10.1007/s00063-018-0452-8
2. . Position paper for the organization of ECMO programs for cardiac failure in adults. Intensive Care Med. 2018 Jun;44(6):717–29. http://dx.doi.org/10.1007/s00134-018-5064-5 PubMed
3.  Unconventional Volume-Outcome Associations in Adult Extracorporeal Membrane Oxygenation in the United States. Ann Thorac Surg. 2016 Aug;102(2):489–95. http://dx.doi.org/10.1016/j.athoracsur.2016.02.009 PubMed
4. . Association of hospital-level volume of extracorporeal membrane oxygenation cases and mortality. Analysis of the extracorporeal life support organization registry. Am J Respir Crit Care Med. 2015 Apr;191(8):894–901. http://dx.doi.org/10.1164/rccm.201409-1634OC PubMed
5. . Volume-Outcome Relationships in Extracorporeal Membrane Oxygenation: Retrospective Analysis of Administrative Data From Pennsylvania, 2007-2015. ASAIO J. 2018 Jul/Aug;64(4):450–7. http://dx.doi.org/10.1097/MAT.0000000000000675 PubMed
7.  Empfehlungen zur extrakorporalen kardiopulmonalen Reanimation (eCPR). Med Klin Intensivmed Notf Med. 2018;113(6):478–86. http://dx.doi.org/10.1007/s00063-018-0452-8
8. . Position paper for the organization of extracorporeal membrane oxygenation programs for acute respiratory failure in adult patients. Am J Respir Crit Care Med. 2014 Sep;190(5):488–96. http://dx.doi.org/10.1164/rccm.201404-0630CP PubMed
9. . Position article for the use of extracorporeal life support in adult patients. Eur J Cardiothorac Surg. 2011 Sep;40(3):676–80. http://dx.doi.org/10.1016/j.ejcts.2011.05.011 PubMed
10.  Positionspapier der Österreichischen Kardiologischen Gesellschaft zum Einsatz der extrakorporalen Membranoxygenation (ECMO) bei Erwachsenen kardiologischen Patienten. Med Klin Intensivmed Notf Med. 2015;110(6):407–20. http://dx.doi.org/10.1007/s00063-015-0052-9
11. . ECMO Cardio-Pulmonary Resuscitation (ECPR), trends in survival from an international multicentre cohort study over 12-years. Resuscitation. 2017 Mar;112:34–40. http://dx.doi.org/10.1016/j.resuscitation.2016.12.009 PubMed Edifix has not found an issue number in the journal reference. Please check the volume/issue information. (Ref. 11 "Richardson, Schmidt, Bailey, Pellegrino, Rycus, Pilcher, 2017")
12.  In-Hospital Neurologic Complications in Adult Patients Undergoing Venoarterial Extracorporeal Membrane Oxygenation: Results From the Extracorporeal Life Support Organization Registry. Crit Care Med. 2016 Oct;44(10):e964–72. http://dx.doi.org/10.1097/ccm.0000000000001865   http://dx.doi.org/10.1097/CCM.0000000000001865 PubMed Crossref reports the DOI should be "10.1097/CCM.0000000000001865", not "10.1097/ccm.0000000000001865". Edifix has used the Crossref-supplied DOI. (Ref. 12 "Lorusso, Barili, Mauro, Gelsomino, Parise, Rycus, et al., 2016")
13. (2011). Infections acquired during extracorporeal membrane oxygenation in neonates, children, and adults. Pediatr Crit Care Med, 12(3), 277-281. doi: http://dx.doi.org/10.1097/PCC.0b013e3181e28894 (Bizzarro, Conrad, Kaufman, & Rycus, 2011) .
14. . Defining risk for infectious complications on extracorporeal life support. J Pediatr Surg. 2011 Dec;46(12):2260–4. http://dx.doi.org/10.1016/j.jpedsurg.2011.09.013 PubMed
15. . Association of bleeding and thrombosis with outcome in extracorporeal life support. Pediatr Crit Care Med. 2015 Feb;16(2):167–74. http://dx.doi.org/10.1097/pcc.0000000000000317   http://dx.doi.org/10.1097/PCC.0000000000000317 PubMed
16.  Neurologic complications in neonates supported with extracorporeal membrane oxygenation. An analysis of ELSO registry data. Intensive Care Med. 2013 Sep;39(9):1594–601. http://dx.doi.org/10.1007/s00134-013-2985-x PubMed
17. . Epidemiology of Stroke in Pediatric Cardiac Surgical Patients Supported With Extracorporeal Membrane Oxygenation. Ann Thorac Surg. 2015 Nov;100(5):1751–7. http://dx.doi.org/10.1016/j.athoracsur.2015.06.020 PubMed
18. . Impact of Kidney Disease on Survival in Neonatal Extracorporeal Life Support. Pediatr Crit Care Med. 2015 Jul;16(6):576–82. http://dx.doi.org/10.1097/pcc.0000000000000414   http://dx.doi.org/10.1097/PCC.0000000000000414 PubMed
19.  Simultaneous Venoarterial Extracorporeal Membrane Oxygenation and Percutaneous Left Ventricular Decompression Therapy with Impella Is Associated with Improved Outcomes in Refractory Cardiogenic Shock. ASAIO J. 2019;65(1):21-8; http://dx.doi.org/10.1097/mat.0000000000000767   http://dx.doi.org/10.1097/MAT.0000000000000767 PubMed
20. (2017). Concomitant implantation of Impella on top of veno-arterial extracorporeal membrane oxygenation may improve survival of patients with cardiogenic shock. Eur J Heart Fail. Retrieved from http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/778/CN-01245778/frame.html doi: http://dx.doi.org/10.1002/ejhf.668
21.  Extracorporeal life support with left ventricular decompression-improved survival in severe cardiogenic shock: results from a retrospective study. PeerJ. 2017 Sep;5:e3813. http://dx.doi.org/10.7717/peerj.3813 PubMed Edifix has not found an issue number in the journal reference. Please check the volume/issue information. (Ref. 21 "Schmack, Seppelt, Weymann, Alt, Farag, Arif, et al., 2017")
22.  Beneficial effects of levosimendan on survival in patients undergoing extracorporeal membrane oxygenation after cardiovascular surgery. Br J Anaesth. 2016 Jul;117(1):52–8. http://dx.doi.org/10.1093/bja/aew151 PubMed
23. . Duration of veno-arterial extracorporeal life support (VA ECMO) and outcome: an analysis of the Extracorporeal Life Support Organization (ELSO) registry. Crit Care. 2017 Mar;21(1):45. http://dx.doi.org/10.1186/s13054-017-1633-1 PubMed
24. . (2015). Ultrasound Guidance for Extra-corporeal Membrane OxygenationGeneral Guidelines .
25.  Predictors of successful extracorporeal membrane oxygenation (ECMO) weaning after assistance for refractory cardiogenic shock. Intensive Care Med. 2011 Nov;37(11):1738–45. http://dx.doi.org/10.1007/s00134-011-2358-2 PubMed
26.  Functional evaluation of sublingual microcirculation indicates successful weaning from VA-ECMO in cardiogenic shock. Crit Care. 2017 Oct;21(1):265. http://dx.doi.org/10.1186/s13054-017-1855-2 PubMed
27.  Weaning of extracorporeal membrane oxygenation using continuous hemodynamic transesophageal echocardiography. J Thorac Cardiovasc Surg. 2013 Dec;146(6):1474–9. http://dx.doi.org/10.1016/j.jtcvs.2013.06.055 PubMed
28. Vasoactiveinotropic score is associated with outcome after infant cardiac surgery: an analysis from the Pediatric Cardiac Critical Care Consortium and Virtual PICU System Registries. Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. 2014;15(6):529-37.
29. . Extracorporeal life support for cardiogenic shock: influence of concomitant intra-aortic balloon counterpulsation. Eur J Cardiothorac Surg. 2014 Aug;46(2):186–92. http://dx.doi.org/10.1093/ejcts/ezu005 PubMed
30.  Effects of Additional Intra-aortic Balloon Counter-Pulsation Therapy to Cardiogenic Shock Patients Supported by Extra-corporeal Membranous Oxygenation. Sci Rep. 2016 Apr;6(1):23838. http://dx.doi.org/10.1038/srep23838 PubMed
31. . The Effect of Intraaortic Balloon Pumping Under Venoarterial Extracorporeal Membrane Oxygenation on Mortality of Cardiogenic Patients: An Analysis Using a Nationwide Inpatient Database. Crit Care Med. 2016 Nov;44(11):1974–9. http://dx.doi.org/10.1097/CCM.0000000000001828 PubMed
32.  Concomitant implantation of Impella® on top of veno-arterial extracorporeal membrane oxygenation may improve survival of patients with cardiogenic shock. Eur J Heart Fail. 2017 Mar;19(3):404–12. http://dx.doi.org/10.1002/ejhf.668 PubMed
33.  Clinical impact of intra-aortic balloon pump during extracorporeal life support in patients with acute myocardial infarction complicated by cardiogenic shock. BMC Anesthesiol. 2014 Apr;14(1):27. http://dx.doi.org/10.1186/1471-2253-14-27 PubMed
34.  Intra-aortic balloon pump protects against hydrostatic pulmonary oedema during peripheral venoarterial-extracorporeal membrane oxygenation. Eur Heart J Acute Cardiovasc Care. 2018 Feb;7(1):62–9. http://dx.doi.org/10.1177/2048872617711169 PubMed

With the comment function, we offer space for an open and critical exchange of expertise. We publish comments as long as they comply with our guidelines.